NASDAQ:CLDX - Celldex Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $50.33
  • Forecasted Upside: 18.15 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$42.60
▼ -1.73 (-3.90%)

This chart shows the closing price for CLDX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Celldex Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLDX

Analyst Price Target is $50.33
▲ +18.15% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Celldex Therapeutics in the last 3 months. The average price target is $50.33, with a high forecast of $66.00 and a low forecast of $35.00. The average price target represents a 18.15% upside from the last price of $42.60.

This chart shows the closing price for CLDX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Celldex Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/1/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/25/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/22/2021GuggenheimInitiated CoverageBuy$66.00Low
7/12/2021HC WainwrightBoost Price TargetBuy$36.00 ➝ $50.00High
2/23/2021HC WainwrightBoost Price TargetBuy$25.00 ➝ $36.00Medium
2/23/2021Cantor FitzgeraldBoost Price TargetOverweight$22.00 ➝ $35.00Medium
11/17/2020Lifesci CapitalReiterated RatingOutperformHigh
10/19/2020HC WainwrightBoost Price TargetBuy$16.00 ➝ $25.00High
7/1/2020Cantor FitzgeraldBoost Price TargetOverweight$12.00 ➝ $18.00Medium
6/12/2020Cantor FitzgeraldBoost Price TargetOverweight$8.00 ➝ $12.00High
3/27/2020HC WainwrightReiterated RatingBuy$19.00 ➝ $16.00High
2/20/2020Cantor FitzgeraldInitiated CoverageOverweight$8.00High
11/11/2019HC WainwrightReiterated RatingBuy$19.00Low
5/8/2019HC WainwrightSet Price TargetBuy$19.00High
4/2/2019HC WainwrightSet Price TargetBuy$19.00Medium
1/15/2019Bank of AmericaUpgradeNeutral ➝ BuyLow
11/19/2018HC WainwrightSet Price TargetBuy$30.00High
11/12/2018HC WainwrightReiterated RatingBuy$30.00High
8/10/2018Jefferies Financial GroupReiterated RatingHoldHigh
8/9/2018CowenReiterated RatingHoldLow
8/9/2018HC WainwrightSet Price TargetBuy$30.00High
6/4/2018HC WainwrightSet Price TargetBuy$30.00Low
5/17/2018HC WainwrightSet Price TargetBuy$30.00Low
5/10/2018CowenReiterated RatingHoldLow
4/17/2018Cantor FitzgeraldDowngradeOverweight ➝ Neutral$45.00Low
4/16/2018CowenDowngradeOutperform ➝ Market PerformHigh
4/16/2018HC WainwrightSet Price TargetBuy$45.00High
3/8/2018SVB LeerinkReiterated RatingMarket Perform ➝ Market Perform$60.00 ➝ $45.00High
3/8/2018HC WainwrightReiterated RatingBuy$150.00High
3/7/2018Cantor FitzgeraldReiterated RatingBuy$135.00High
2/9/2018HC WainwrightSet Price TargetBuy$150.00High
12/6/2017WBB SecuritiesReiterated RatingBuy$150.00Low
11/7/2017HC WainwrightReiterated RatingBuyN/A
9/26/2017Cantor FitzgeraldReiterated RatingBuy$135.00Low
8/9/2017HC WainwrightSet Price TargetBuy$150.00High
8/1/2017HC WainwrightReiterated RatingBuy ➝ Buy$150.00High
6/29/2017AegisReiterated RatingBuyMedium
6/6/2017CowenReiterated RatingBuyHigh
5/11/2017Jefferies Financial GroupReiterated RatingHold$60.00 ➝ $52.50High
3/21/2017AegisReiterated RatingBuyLow
3/15/2017Jefferies Financial GroupLower Price TargetHold$75.00 ➝ $60.00Medium
3/15/2017HC WainwrightReiterated RatingBuy$90.00Medium
11/10/2016Roth CapitalReiterated RatingBuy$105.00N/A
11/8/2016WedbushReiterated RatingNeutral$45.00N/A
11/8/2016Cantor FitzgeraldReiterated RatingBuy$135.00N/A
11/7/2016AegisInitiated CoverageBuyN/A
11/2/2016Roth CapitalSet Price TargetBuy$105.00N/A
10/10/2016Cantor FitzgeraldReiterated RatingBuy$135.00N/A
10/4/2016Brean CapitalInitiated CoverageBuy$240.00N/A
8/11/2016Jefferies Financial GroupReiterated RatingHold$60.00 ➝ $75.00N/A
8/9/2016WedbushReiterated RatingNeutral$45.00N/A
8/5/2016Jefferies Financial GroupBoost Price TargetHold$75.00N/A
(Data available from 7/25/2016 forward)
Celldex Therapeutics logo
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Read More

Today's Range

Now: $42.60
Low: $41.88
High: $44.91

50 Day Range

MA: $32.31
Low: $26.39
High: $44.60

52 Week Range

Now: $42.60
Low: $9.59
High: $46.42

Volume

837,336 shs

Average Volume

1,638,680 shs

Market Capitalization

$1.98 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.05

Frequently Asked Questions

What sell-side analysts currently cover shares of Celldex Therapeutics?

The following equities research analysts have issued stock ratings on Celldex Therapeutics in the last year: Cantor Fitzgerald, Guggenheim, HC Wainwright, Lifesci Capital, and Zacks Investment Research.
View the latest analyst ratings for CLDX.

What is the current price target for Celldex Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Celldex Therapeutics in the last year. Their average twelve-month price target is $50.33, suggesting a possible upside of 18.2%. Guggenheim has the highest price target set, predicting CLDX will reach $66.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $35.00 for Celldex Therapeutics in the next year.
View the latest price targets for CLDX.

What is the current consensus analyst rating for Celldex Therapeutics?

Celldex Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CLDX will outperform the market and that investors should add to their positions of Celldex Therapeutics.
View the latest ratings for CLDX.

What other companies compete with Celldex Therapeutics?

How do I contact Celldex Therapeutics' investor relations team?

Celldex Therapeutics' physical mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The biopharmaceutical company's listed phone number is 908-200-7500 and its investor relations email address is [email protected] The official website for Celldex Therapeutics is www.celldex.com.